<DOC>
	<DOC>NCT01217008</DOC>
	<brief_summary>The purpose of the study is to evaluate the safety of GRNOPC1 administered at a single time-point between 7 and 14 days post injury, inclusive, to patients with neurologically complete spinal cord injuries (SCI).</brief_summary>
	<brief_title>Safety Study of GRNOPC1 in Spinal Cord Injury</brief_title>
	<detailed_description />
	<mesh_term>Wounds and Injuries</mesh_term>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<criteria>Major Neurologically complete, traumatic SCI (ASIA Impairment Scale A), zone of partial preservation &lt; 5 levels Last fully preserved neurological level from T3 through T11 From 18 through 65 years of age at time of injury Single spinal cord lesion Informed consent for this protocol and the companion long term followup protocol must be provided and documented (i.e., signed informed consent forms) no later than 11 days following injury Able to participate in an elective surgical procedure to inject GRNOPC1 714 days following SCI Major SCI due to penetrating trauma Traumatic anatomical transection or laceration of the spinal cord Any concomitant injury or preexisting condition that interferes with the performance, interpretation or validity of neurological examinations Inability to communicate effectively with neurological examiner Significant organ damage or systemic disease that would create an unacceptable risk for surgery or immunosuppression History of any malignancy Pregnant or nursing women Body mass index (BMI) &gt; 35 or weight &gt; 300 lbs. Active participation in another experimental procedure/intervention</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Spinal Cord Injury</keyword>
	<keyword>GRNOPC1</keyword>
</DOC>